Colon-MarCarePlex™ Technology is Offered for Sale/License

JERUSALEM, Aug. 1, 2014 /PRNewswire-iReach/ -- Bio-MarCare Technologies, a leader in the development of plasma RNA biomarkers for colorectal cancer (CRC), is offering for sale its proprietary Colon-MarCarePlex™ technology for the pre-cancerous polyps screening in blood. The purchaser will receive all intellectual property (IP) rights, know-how and current business relationships associated with MarCarePlex™ technology.

Breakthrough Blood RNA Biomarkers Push Accurate Colorectal Cancer Screening Test Forward

Circulating free RNAs are considered to be fragile and more susceptible to degradation. We were able to develop a breakthrough reliable and reproducible procedure to purify and stabilize RNA extracted from plasma sufficiently intact to allow analysis by reverse transcription-PCR. RNA biomarker selection process was preformed utilizing a bioinformatics analysis approach along with gene expression array in patient's samples and peer reviews publications. 817 candidate genes were found to be common between the gene array expression analysis and literature data. Top 100 genes which showed the greatest expression levels were tested by qPCR.  Patients were recruited prospectively from 3 clinical sites. For biomarker discovery, plasma RNA was extracted from 3 patient study:  i) Colonoscopy negative individuals;  ii) Advanced adenomatous polyps (pre-cancer) – confirmed by colonoscopy; and iii) Colorectal cancer patients (stages I-III). For the clinical validation trial the intended use screening population is asymptomatic individuals. Thus, the trial will prove that patients can be turned compliant to this screening blood test. 

Eight biomarkers were selected for extensive clinical analysis using 1000 blood samples. Carefully chosen marker combinations formed a solid base to become a sensitive screening assay. A US patent application was filed in light of Supreme Court Prometheus-Mayo decisions and covers multi RNA biomarker panel combination for colorectal cancer screening

Colon-MarCarePlex™: Powerful Biomarker Panels Based on Solid and Proven Technology

The clinical data pinpointed on several leading marker combinations. For Pre-Cancer Predication:  statistical analysis included 46 colonoscopy negative patients and 38 patients with advanced polyp. For a combination model of ID002 with ID005 the ROC analysis and AUC were 70.5%, 95% asymptotic (CI: 58.5%-82.5%), p value <0.001. At Max Youdin Index point performance was sensitivity of 60% and specificity of 87%. These performance characteristics represent the highest accuracy level among other alternatives on market and under development.

A Meaningful Market with Room to Grow

Because patients at earlier stages of CRC are often asymptomatic, CRC screening allows for early identification of cancer at stages where treatment is more likely to be effective. Five-year survival rates for Stages I-II CRC cases are 94% and 82%, respectively. Colon-MarCarePlex assay is a non-inferiority assay for CRC sensitivity when compared to fecal test (FIT) and a superiority test for pre-cancer (advanced polys) sensitivity. Given that identification of pre-cancer is important for reduction of CRC incidence and that detection of CRC at early stages has the potential to significantly reduce mortality, an optimal new screening tool should have high sensitivity for CRC and also capable to identify pre-cancer. BioMarCare high sensitivity in plasma enables screening independently of tumor location and can be with great clinical utility due to patients' compliance.

Bio-Marcare Technologies Ltd. is offering for sale all intellectual property rights and RNA biomarkers panel rights related to its Colon-MarCarePlex™ technology. To learn more about this opportunity, please contact us before August 22th, 2014.

For further information, please contact...

AAD Health, LLC,
Tel: +1-805-791-6696 • Fax: +1-805-498-6867

Media Contact: BioMarCare Technologies Ltd., Biomarcare Technologies Ltd., +972-52-3275719, [email protected]

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE BioMarCare Technologies Ltd.